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Disease progressionDeregulation of the oxidative cascade of poly-unsaturated fatty acids (PUFAs) has been associated with several
cancers, including chronic lymphocytic leukemia (B-CLL). Leukotriene B4 (LTB4), a metabolite of arachidonic
acid (AA), is produced by B-CLL and contributes to their survival. The aim of the present study was to analyze
the activity of the oxidative cascade of PUFAs in B-CLL. Puriﬁed B cells from patients and normal B CD5 positive
cells were subjected to ﬂow cytometry, Western-blot and RT-qPCR analyses. LTB4 plasma and intracellular con-
centrationswere determined by ELISA. Our results showed that aggressive B-CLL tumor cells, i.e. cellswith an an-
nual proliferation index above 2, over-expressed calcium-dependent and calcium-independent phospholipases
A2 (cPLA2-alpha and iPLA2-beta, respectively), 5-lipoxygenase (5LOX) and leukotriene A4 hydroxylase
(LTA4H). Intracellular LTB4 levelswere lower in themost aggressive cells than in cellswith a smaller proliferation
index, despite equivalent plasma levels, and lower expression of cytochrome P450 4F3A (CYP4F3A), one major
enzyme involved in LTB4 inactivation. Since BLT2, a LTB4 membrane receptor was also more often expressed
on aggressive tumor cells, and since a BLT2 inhibitor signiﬁcantly impaired B-CLL viability in vitro, we propose
that LTB4 was efﬁciently trapped onto BLT2 present on aggressive tumors, thereby eliciting an autocrine re-
sponse. Taken together our results demonstrate a major deregulation of the pathway leading to LTB4 synthesis
and degradation in B-CLL cells, and provide a framework for understanding how these modiﬁcations promote
cell survival and proliferation, especially in the most aggressive BCLL.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult
blood cancer in theWestern world. CLL is characterized by the accumu-
lation of mature-looking immune-incompetent lymphocytes. B-CLL
lymphocytes are the most frequent, representing 95% of the CLL cases.
B-CLL manifests a variable clinical course characterized by progressive
disease and short survival in approximately half of the cases, and a
relatively stable disease and normal lifespan in the remaining patients.
B-CLL lymphocytic tumor cells have extended survival but low prolifer-
ative potential [1]. Apoptosis of B-CLL leukemia cells is regulated
by multiple signal transduction pathways [2–5]. Several studies haveen nutrition humaine, Faculté
rance. Tel.: +33 298 017 901;
ec).
.stressed the importance of the medullary environment for tumor
B-CLL cells survival, through cellular interactions and cytokines or
hormone receptors' activation [3–5].
Activation of the oxidative cascade of polyunsaturated fatty
acids (PUFAs) has been associated with several cancers, including
B-CLL [6,7]. Speciﬁcally, phospholipase A2 (PLA2) activation results in
arachidonic acid release that can be metabolized either into leukotri-
enes by lipoxygenases (LOX), or into prostaglandins by cyclooxygenases
(COX) [6–9]. Cyclooxygenase 2 (COX2) expression in B-CLL tumor cells
has been reported and associated with enhanced B-CLL lymphocytic
tumor cells survival due to increased production of PGE2 and PGF2
[10,11]. A paracrine loop has now clearly been demonstrated, which in-
volves non-malignant leukocytes and nurse-like cells, but contribution
of an autocrine loop to B-CLL lymphocytic tumor cells survival cannot
be ruled out [3,12]. B-CLL tumor lymphocytes have indeed been
shown to produce leukotriene B4 (LTB4) and to express its high afﬁnity
receptor BLT1 [13]. LTB4 seems to contribute to CD40-dependent acti-
vation of chronic B lymphocytic leukemia cells [13]. CD40 engagement
severely reduces B lymphocytes' apoptosis, and contributes to B-CLL
cells survival [14].
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BLT1 and BLT2, LTB4 can also be omega-hydroxylated by CYP4F3, a
member of the cytochrome P450 superfamily. This results in its inacti-
vation and in the formation of 20-OH-LTB4, described as an inhibitor
of BLT1 expression [15]. CYP4F3 expression results from the assembly
of two distinct mRNAs, produced by tissue-speciﬁc alternative splicing,
and encoding the CYP4F3A and CYP4F3B proteins [16]. CYP4F3A is
mostly expressed in leukocytes and CYP4F3B in the liver [17]. CYP4F3
is also expressed in activated CD38 positive lymphocytes, but neither
the sub-cell populations nor the isoforms have so far been characterized
[17,18]. LTB4 was recently reported to control human B lymphopoiesis
and stem cell differentiation and proliferation, through the activation
of its receptors BLT1 and BLT2 [19,20]. LTB4 and prostaglandins also
activate members of the Peroxisome Proliferator Activated Receptor
(PPAR) family of transcription factors. LTB4 binds PPAR-alpha, which
in turn regulates the oxidative degradation of PUFAs and their deriva-
tives, including LTB4 [21,22]. Moreover, PPAR-gamma, anothermember
of the PPAR family, contributes to the regulation of inﬂammation
[23,24]. It can also bind oxidized lipids, including 15-deoxy-delta 12-
14-PGJ2, a metabolite of PGD2 [23,24].
Recent studies have shown that PPAR-gamma is a key regulator of
B cell lineage differentiation and proliferation. Its activation prevents
interleukin-6-dependent proliferation of myeloma cells [25] and results
in apoptosis of normal B murine lymphocytes, in caspase-3- and
caspase-9-dependent manner [14]. Furthermore, in cooperation with
other transcription factors, PPAR-gamma represses the expression of
several membrane receptors, including Toll receptors involved in
B-CLL leukemia cells survival [26]. The G0/G1 switch gene 2 is a PPAR-
gamma target and, possibly, a PPAR-alpha target [27], while PPAR-
gamma also regulates the transcription of cyclin D1 [28].
In light of these data, it seemed of interest to us to explorewhether a
deregulation in the activation of the oxidative cascade of PUFAs may
occur in B-CLL lymphocytic leukemia cells. In the present study, we
analyzed the expression of several genes and proteins involved in
the arachidonic acid-dependent transduction pathway, both in low-
and in high-progressing B-CLL, in comparison with normal B CD5 posi-
tive cells.
2. Material and methods
2.1. Patients
Fifty-six patients fulﬁlling the criteria for the diagnosis of B-CLLwere
enrolled in the study, and scored clinically according to Matutes et al.
and Binet classiﬁcation (Table 1) [29,30]. Disease stages were distribut-
ed as follows: 40 stage A, 23 men plus 17 women (50 to 90 years old,
mean age 70); 11 stage B, 7 men plus 4 women (45 to 80 years old,
mean age 61); and 5 stage C, 2 men plus 3 women (54 to 76 years
old, mean age 68). The median follow-up was 5 years. Patients were
either untreated or had not received treatment for 6 months before
the study. Tonsils from 2 to 5 years old children undergoing routine
tonsillectomy were also taken. Peripheral blood samples and tonsils
were obtained after informed consent. The protocol was approved by
the Institutional Review Board at Brest University under the reference
2008-214. Disease was considered as highly progressing when the
number of B-CD5 positive lymphocytes at year n + 1 was at least
twice as high as the number of B-CD5 positive lymphocytes at year n,
and slowly progressing otherwise.
2.2. Cell preparation and ﬂow cytometry
Mononuclear cells were isolated by Ficoll density-gradient centrifu-
gation. B cells were puriﬁed by negative selection usingmagnetic beads
(B cell isolation kit, Miltenyi Biotech) according to the manufacturer's
instructions. Following isolation, more than 95% of the isolated B-CLL
cells expressed CD5 and CD19, as ascertained using PE-conjugatedanti-CD19, FITC anti-CD3 and PC5 anti-CD5 monoclonal antibodies
and the Epics-XL FACS cytometer (Beckman-Coulter for antibodies
and cytometer). For healthy B-CD5 positive cells puriﬁcation from
tonsils, B cells were submitted to a magnetic positive selection before
cytometry analysis. The analysis of BLT1 and BLT2 membrane expres-
sion was performed on at least 5 × 105 puriﬁed cells. Antibodies were
from Sigma-Aldrich, catalog numbers MFCD04118542 for BLT1 and
MFCD04118543 for BLT2.
2.3. Western blotting
Total proteins were isolated immediately after cell puriﬁcation, as
previously described [31]. Brieﬂy, cells (1 × 107) were lysed for 30 min
on ice in a buffer containing 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM
EGTA, 50 mM NaCl, 2 mM Na3VO4, 100 mM NaF, 4 mM NaH2PO4, 1 μM
phenylmethylsulfoxide ﬂuoride, 2% Triton, 2% Nonidet P40, 5 mg/ml
leupeptin, and 5 mg/ml aprotinin. Equal amounts of proteins (50 μg)
were loaded on 8–12% SDS polyacrylamide gels, which were then trans-
ferred onto PVDF membrane (Hybond P, Amersham), probed with
appropriate antibodies and revealed by chemiluminescence. The signal
was quantiﬁed using a densitometry software (Bioproﬁl, Vileber-
Lourmat, France). Protein expression was normalized using beta-actin
as an internal standard. Primary antibodies were purchased from
Abcam for anti-actin (catalog number ab1801, rabbit polyclonal),
iPLA2 (ab23706, rabbit polyclonal, does not cross-react with cPLA2 or
sPLA2), pan-PLA2 (ab9014, sheep polyclonal), COX1 (ab695, mouse
monoclonal), and COX2 (ab15191, rabbit polyclonal), from cell signal-
ing technology for cPLA2 (catalog number 2832, rabbit polyclonal,
does not cross-react with iPLA2 or sPLA2). Primary antibodies were
diluted at 1/1000, except for anti-pan-PLA2 which is at 1/2500. The
following reagents were purchased from GE Healthcare (Amersham
Biosciences): Goat anti-rabbit IgG HRP-linked (catalog number RPN
4301, used 1/5000), sheep anti-mouse IgG HRP-linked (RPN4201,
used 1/5000) and chemiluminescence kit (ECL plus, RPN 2132). Rabbit
anti-sheep IgG HRP-linked was obtained from Abcam and used at
1/10,000 (ab6747).
2.4. LTB4 quantiﬁcation
LTB4 was quantiﬁed from either plasma (n = 15 controls, n = 25
patients) or cell lysates (n = 5 controls, n = 25 patients). Ten million
cells were lysed as recommended by the manufacturer (Cayman
Biochemical) and subjected to analysis.
2.5. RNA extraction and quantitative RT-PCR
Total RNA was extracted with the TRIzol® (Life Technologies) solu-
tion according to the manufacturer's instructions. Total RNA (200 ng)
was used for ﬁrst-strand cDNA synthesis with the High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems). Quantitative RT-PCR
was performed using the Power SYBR Green PCR Master Mix (Applied
Biosystems) for all transcripts except PPAR-alpha and PPAR-gamma,
analyzed with speciﬁc TaqMan probes, according to the manufacturer's
instructions with an ABI 7000 or 7300 real-time PCR system (Applied
Biosystems). All determinations were performed in duplicate and
normalized against GAPDH as an internal control gene. The results
were expressed as the relative gene expression using the DeltaDeltaCt
method. Fold change= 2−[(Ct target gene in sample−CtGAPDH in sam-
ple)− (Ct target gene innormalCD5positiveB cells−CtGAPDH innormal
CD5 positive B cells)] [32]. Primer sequences are listed in Table 2.
2.6. Cell proliferation assay and reagents
Cell viability and proliferationwere assessed using a MTT cell prolif-
eration assay kit, using the optical density as a measure (570 nm) as
recommended by the manufacturer (Cayman Chemical). Puriﬁed B
Table 1
Patients' characteristics (proliferation index was calculated by dividing the number of B-CD5 positive lymphocytes at year n + 1 by the number of B-CD5 positive lymphocytes at year n).
Patient number Age (years) Gender Lymphocytes (109/L) Binet stage %CD38 pos cells Proliferation index Matutes score Follow-up (years)
1 74 M 45 A 3 1.01 5 7
2 54 M 48 A 1 1.20 4 9
3 68 M 15 A 4 1.02 5 2
4 75 M 35 A 2 4.36 4 4
8 77 F 31.7 A 72 3.20 5 10
9 58 M 21.2 A 0 1.43 3 5
12 72 M 22 A 0 1.10 4 11
13 50 M 24 A 2 1.30 4 2
14 67 M 23 A 0 1.20 5 3
16 78 F 33 A 7 4.60 5 8
17 83 F 50 A 0 1.10 5 4
20 55 M 35 A 0 1.03 5 5
22 76 M 21.4 A 2 3.20 4 3
24 58 F 25 A 1 1.28 3 9
25 76 F 40.7 A 8 2.82 4 4
26 78 F 40 A 3 1.32 4 10
27 60 F 47.8 A 0 1.27 5 1
28 59 M 19 A 5 2.84 5 3
29 56 M 26 A 1 1.19 4 2
30 76 F 22 A 0 1.00 4 7
31 76 F 20 A 6 1.60 3 3
32 79 F 25 A 0 1.16 3 10
35 81 M 27.5 A 2 1.14 5 1
36 80 M 25 A 0 1.76 4 2
37 73 F 25 A 16 1.19 5 8
39 61 M 18 A 9 1.06 5 1
40 62 M 44 A 0 1.75 5 7
42 75 M 64 A 0 3.62 5 4
43 82 M 74 A 0 1.89 4 8
44 90 M 55 A 1 1.13 4 5
45 73 F 52 A 2 2.05 3 7
46 71 M 30 A 1 1.03 4 1
48 70 M 33 A 3 1.48 3 5
49 62 F 17 A 1 1.06 3 3
50 67 F 29 A 2 1.21 3 5
53 77 F 21 A 0 2.38 5 11
54 81 F 85.1 A 1 1.28 5 7
55 72 M 46 A 6 1.24 4 5
18 58 M 25 A 1 1.30 4 5
57 73 F 32 A 13 4.63 5 1
10 45 F 68 B 1 2.85 4 1
11 50 M 22 B 2 1.60 5 3
15 58 F 37 B 37 3.20 4 5
21 74 F 57 B 3 1.21 5 2
23 80 M 59 B 7 1.12 5 2
33 77 M 50.5 B 0 1.08 4 1
41 60 F 82 B 0 1.34 5 1
47 58 M 14 B 27 1.07 5 6
51 53 M 42 B 49 2.98 4 2
52 54 M 33 B 44 2.65 3 4
56 66 M 19 B 70 10.60 2 1
5 65 F 20 C 18 10.00 5 4
6 54 M 123 C 3 6.10 5 3
7 76 F 110 C 54 7.85 3 6
34 69 F 18 C 2 8.44 4 2
38 57 M 120 C 31 8.50 4 2
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of 5 × 104 cells perwell in RPMI 1640mediumwith 10% fetal calf serum.
To addresswhether 12-HHT, ametabolite of PGH2 through the action of
thromboxane synthase (TXAS), may be involved in B-CLL cells survival,
20 μM ozagrel, a synthetic TXAS inhibitor, was added to the medium.
The U78502 anti-BLT1 speciﬁc and LY255283 anti-BLT2 speciﬁc inhibi-
tors were also used at 1.5 μM and 10 μM, respectively. All the inhibitors
were added 30 min before adding LTB4 (150 nM).
2.7. Statistical analysis
Comparisons between groupswere performed using Chi-square test
or ANOVA1 test and Bonferroni correctionwith the PRISM Software. For
quantiﬁcation, expression is given as mean ± SEM.3. Results
3.1. Expression of c- and i-PLA2
To determine whether B-CLL cells and their normal counterparts,
normal B CD5 positive lymphocytes, expressed PLA2 isoforms, we
made use of a pan-PLA2 antibody in a Western-blotting analysis. Two
major bands of 85 and 77 kDawere distinguished, thatmay respectively
correspond to cPLA2-alpha and iPLA2-beta (data not shown). To con-
ﬁrm this result, we used antibodies speciﬁc for either cPLA2 or iPLA2,
with actin as a loading control. As shown in Fig. 1A, both proteins,
cPLA2-alpha and iPLA2-beta, could be detected in all specimens (n =
12 controls and n= 56 patients). No truncated forms of iPLA2were de-
tected in any of the specimens analyzed. The expression of iPLA2-beta
Table 2
Primers' list.











PPAR-alpha Ref. Hs 00231882_m1(FAM)
Sequences are the property of Applied Biosystems
PPAR-beta Ref. Hs 00234592_m1(FAM)
Sequences are the property of Applied Biosystems
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However, no difference was found according to disease stage. Although
cPLA2-alpha expression was not higher in stage A leukemic cells (n =
40) than in normal B CD5 positive cells (n = 12), an increase was ob-
served for B and C stages (n= 11 and n = 5, respectively) in compari-
son with normal B CD5 positive cells and stage A leukemic cells. The
same analyses were then performed to see whether variations could
be observed for a same patient (Fig. 2). Tumor cells were collected
every six months for n = 43 patients over the follow-up time.
Twenty-four patients with a slowly progressing disease were analyzed
(18 stage A and 6 stage B patients) and 19 patients with a rapidly
progressing disease (9 stage A, 5 stage B and 5 stage C patients). In the
group with a slowly progressing disease (less than one cell population
doubling per year), none of the PLA2 isoforms showed a signiﬁcant
variation of expression within 36 months of follow-up time (Fig. 2A). In
contrast, iPLA2-beta and cPLA2-alpha increased over a 2 year period for
the patients with a rapidly progressing disease. This was specially ob-
served for cPLA2-alpha, whose expression level strongly correlated with
this parameter (p b 5 × 10−3), as compared to iPLA2-beta (p = 0.01)
(Fig. 2B).3.2. Expression of COX, 5LOX, LTA4H, and TXAS
As PLA2 activation results in the generation of bioactive lipids, and
especially arachidonic acid that enters either the lipoxygenases or the
cyclooxygenases pathways, the expression of cyclooxygenases 1 and 2
(COX1, COX2), thromboxane synthase (TXAS), 5-lipoxygenase (5LOX)
and leukotriene A4 hydrolase (LTA4H), was further analyzed. GAPDH
was chosen as an invariant RNA control (Ct = 21.64 ± 0.35 cycles for
control cells (n = 12) and 22.37 ± 0.32 (n = 45) for puriﬁed B-CLL
cells).Fig. 1.Analysis of cPLA2-alpha and iPLA2-beta expression according to disease stage. A: A repres
actin for n = 12 controls and n = 56 patients, as determined by densitometry analysis. ControFive-LOX mRNA expression level was not correlated with disease
stage (n=33, data not shown), but itwas very signiﬁcantly higher in leu-
kemic cells than in normal B CD5positive cells (Fig. 3A, p=0.54× 10−9).
Interestingly, 5LOX mRNA level also correlated with the clinical evolu-
tion, the highest fold changes being found for the rapidly progressing
patients (n = 12, p = 0.0016, Fig. 3B). In parallel, LTA4H expression
was very signiﬁcantly raised in B-CLL cells compared to healthy B CD5
positive cells (p= 1.26 × 10−10, Fig. 3C). However, no statistical corre-
lation was found with the stage of the disease. By contrast, as observed
for 5LOX, the highest fold changes were those of patients with a highly
progressing disease (p = 0.0024, Fig. 3D).
In addition, COX1 and COX2 protein levels were analyzed (with the
apparentMWof 69 and 67 kDa, respectively) (n= 53 samples, Fig. 4A).
COX1 expression remained unchanged in tumor cells compared with
normal B CD5 positive cells. No correlation was evidenced with any
clinical parameter (data not shown). By contrast, COX2 was slightly
overexpressed in tumor cells, at similar levels according to the stage
(p = 0.003, Fig. 4A and B). TXAS was also more expressed in B-CLL
tumor cells than in healthy B CD5 positive cells (p = 0.016, Fig. 4C).
However, no correlation was found with the stage of the disease or
the clinical evolution (data not shown).
As shown in Fig. 5, COX2 expression levelwas also associatedwith the
clinical outcome (p= 0.0021), with the highest expression observed for
the patients with adverse evolution. Nevertheless, this was not observed
for TXAS (p = 0.70, n = 22 patients, data not shown).3.3. Expression of CYP4F3
A consequence of 5LOX and LTA4H activity is the possible production
of LTB4 that can further either be inactivated by CYP4F3, or trapped onto
its receptors BLT1 and BLT2, thereby eliciting a biological response. RT-
qPCR analyses with speciﬁc primers demonstrated that only CYP4F3A,
but not CYP4F3B, was expressed in normal B CD5 positive cells and B-
CLL tumor cells, in agreement with previous reports [15–17]. CYP4F3A
was more expressed in B-CLL tumor cells than in healthy CD5 positive
lymphocytes, ranging between 29 and 2000 folds, for highly (n = 14)
and slowly (n= 25) progressing cases, respectively. In addition, a strong
correlation was observed between CYP4F3A over-expression and the
clinical outcome, with the lowest over-expression being observed for
the fastest growing tumor cells (p = 0.0005, Fig. 6A). The pathways
that determine the fate of LTB4 include 5LOX- and LTA4H-dependent
LTB4 synthesis and CYP4F3-dependent hydroxylation. Considering the
balance between both synthesis and inactivation of LTB4, we calculated
the ratios between the fold-changes of 5LOX and LTA4H and that of
CYP4F3A. As shown in Fig. 6B and C, and in agreement with the re-
sults observed for 5LOX, LTA4H and CYP4F3A expression, this ratio
strongly increased in highly proliferating tumor cells together with
5LOX (p = 0.006, n = 19 slowly progressing vs 10 highly progressingentative blot from aWestern blotting analysis is shown. B:Mean expression normalized to
l stands for healthy B CD5 positive cells (N95% purity as ascertained by ﬂow cytometry).
Fig. 2.Analysis of cPLA2-alpha and iPL2-beta expression and disease progression. Analysis over a 36 months follow-up for slowly progressing (A, n= 24) or 24 months follow-up for rap-
idly progressing (B, n = 19) disease. Two representative series of analyses are shown per group of patients. C and D: Mean expression normalized to actin (densitometry analysis) for
patients with a slowly progressing disease (C, n = 24) or a highly progressing disease (D, n = 19).
2100 N. Guriec et al. / Biochimica et Biophysica Acta 1842 (2014) 2096–2105cases) and LTA4H (p = 0.005, n = 15 slowly progressing vs 7 slowly
progressing cases).3.4. Expression of LTB4 receptors and LTB4 quantiﬁcation
BLT1was slightlymore expressed on B-CLL tumor cells than on their
normal counterparts (p = 0.045), but no correlation was found be-
tween its expression and any clinical parameter (data not shown).
However, BLT2 was more often expressed on tumor cells when the dis-
ease evolved rapidly (35 to 75% positive cells, n = 10, p = 0.003) than
when it evolved slowly (n = 15, Fig. 7A). In the slowly progressing
condition, BLT2 expression varied from 10 to 30% of the cells analyzed
and was not statistically different from that of control cells (n = 12,
10 to 20% of the cells).
LTB4 levels were analyzed independently in plasma and in cells.
Plasma levels were found similar, although a slight, non-statistically
signiﬁcant increase was observed for patients compared to controls
(1055.9 ± 114 pg/ml for n = 15 controls, and 1512.9 ± 415.4 pg/ml
for n = 25 patients, p N 0.05). No correlation was found with any
clinical parameters. However, concentrations in lysates of patient cells
(220.26 ± 16.86 pg LTB4/μg of proteins, n = 25) were signiﬁcantlyFig. 3.Analysis of 5LOX and LTA4Hexpression. A: 5LOXwasmeasuredbyRT-qPCRusingGAPDH
samples. B: Disease progression and 5LOX fold change asmeasured by RT-qPCR using GAPDHas
RT-qPCRusingGAPDHas an internal standard (Ct LTA4H–CtGAPDH) for n=12control samples
RT-qPCR using GAPDH as an internal standard and control cells as reference. Control stands fohigher than those of control cells (121.03 ± 11.23 pg/μg, n = 10,
p = 0.0087). A correlation was found (p = 0.0023) between LTB4
intracellular concentration and the stage of the disease when values
for stage A patients (253.25 ± 19.25 pg/μg, n = 17) were compared
with those obtained for stage B or C patients (150.15 ± 14.62 pg/
μg, n = 8). Moreover, low intracellular concentrations also correlat-
ed with an adverse evolution (p = 0.0008) with concentrations of
262.33 ± 19.25 pg/μg for patients with a slowly evolving disease
(n = 15) and 157.14 ± 14.29 pg/μg for those with a rapidly evolv-
ing disease (n = 10, Fig. 7B). In the last case, concentrations were
closed to those observed in normal B CD5 positive lymphocytes
(121.03 ± 11.23 pg/μg, p = 0.1006, Fig. 7B).3.5. PPAR expression
As LTB4 and prostaglandins bind and activate PPARs, which, in turn
regulate cellular proliferation and differentiation, PPARs' expression
was determined using RT-qPCR. Both PPAR-alpha and PPAR-gamma
were over-expressed in leukemic cells in comparison with healthy B
CD5 positive cells. A major increase was observed for PPAR-alpha
(around 200-fold), while fold changes for PPAR-gamma ranged fromas an internal standard (Ct 5LOX–CtGAPDH) for n=12control samples and n=33 tumor
an internal standard and control cells as reference. C: Expression of LTA4H asmeasured by
and n=22 tumor samples. D:Disease progression and LTA4H fold change asmeasured by
r healthy B CD5 positive cells (N95% purity as ascertained by ﬂow cytometry).
Fig. 4. COX1 and COX2 expression analysis (n= 12 controls, n= 53 patients). A: TheWestern blot analysis is from a typical analysis B:Mean expression of COX1 and COX2 proteins nor-
malized to actin for n= 12 controls and n= 53 patients (densitometry analysis). C: Expression of TXASmeasured by RT-qPCR using GAPDH as an internal standard (Ct TXAS–Ct GAPDH)
for n = 12 control samples and n = 22 tumor samples. Control stands for healthy B CD5 positive cells (N95% purity as ascertained by ﬂow cytometry).
2101N. Guriec et al. / Biochimica et Biophysica Acta 1842 (2014) 2096–21055.95 ± 3.51 to 16.91 ± 8.02 (Table 3). For PPAR-alpha, no correlation
was found between fold change values and any clinical parameter. By
contrast, changes in PPAR-gammaexpression correlatedwith the evolu-
tion of the disease. PPAR-gammawas signiﬁcantlymore over-expressed
in highly proliferating leukemic cells (n = 13) than in those proliferat-
ing slowly (n = 19, p = 0.009, Table 3).
3.6. Inhibition of BLT1, BLT2 and TXAS
We next hypothesized that an autocrine loop might contribute to
B-CLL lymphocytic tumor cells survival. In order to analyze the relative
contribution of LTB4 through BLT1 and BLT2 binding and of 12-HHT, the
high afﬁnity ligand for BLT2 resulting from the action of TXAS on PGH2,
we made use of speciﬁc inhibitors for 6 healthy B CD5 positive controls,
6 patientswith a slowly progressingdisease and 6 patientswith a highly
progressing one. BLT1 and BLT2 cell surface expression, according to the
ﬂow cytometry analysis, was respectively 15 ± 5% and 16 ± 7% for the
controls, 20 ± 5% and 24 ± 7% for the cells of patients with a slowly
progressing disease, and 31 ± 9% and 52 ± 10% for those of patients
with an aggressive one. Survival was evaluated using a MTT assay (op-
tical density read at 570 nm). Without any treatment, the optical densi-
ty was statistically higher for B-CLL cells of patients with an aggressive
disease than that of tumor cells of patients with a slowly progressingFig. 5. COX1 and COX2 expression over a 36 months follow-up for slowly progressing disease (
typical analyses. C and D: Mean expression normalized to actin for patients with a slowly pro
analysis).disease (p = 0.04, Fig. 8). The optical densities for slowly progressing
B-CLL and control cells were not distinct from one another (Fig. 8).
Adding LTB4 allowed an increase of the optical density for B-CLL cells
but not for control cells and this was more important when the disease
was aggressive (p = 0.05 for slowly progressing disease, p = 0.01 for
highly progressingdisease). InhibitingBLT1 before adding LTB4 resulted
in no statistical difference between these two conditions. This was also
observedwhen no LTB4was added. However, adding the BLT2 inhibitor
signiﬁcantly reduced the value of the optical density of B-CLL for pa-
tients with an aggressive disease (p = 0.01) but not for that of control
cells or that of B-CLL cells of patients with a slowly progressing disease.
Adding a BLT2 inhibitor also reduced the survival of B-CLL cells of pa-
tients with adverse evolution but this was not observed for control
cells and tumor cells of patients with no unfavorable evolution. No syn-
ergy or additivity was observed between BLT1 and BLT2 inhibitors, in
any of the conditions tested. Furthermore, inhibition of TXAS with
ozagrel did not result in any signiﬁcant variation of the survival for
any of the cell populations tested.
4. Discussion
The mechanisms governing the occurrence and the progression of
B-CLL are yet poorly understood. This study allowed us to identifyA, n = 24) or highly progressing disease (B, n = 19). TheWestern blot analyses are from
gressing disease (C, n = 24) or a highly progressing disease (D, n = 19) (densitometry
Fig. 6. A: Disease evolution and fold-change in CYP4F3A expression as measured by RT-qPCR. GAPDH was used as an internal standard and healthy B CD5 positive cells as a reference.
B: Disease evolution and ratio between fold changes in 5LOX and CYP4F3A expression. C: Disease evolution and ratio between fold changes in LTA4H and CYP4F3A expression.
Fig. 7. A: Surface expression of BLT1 and BLT2 receptors as assessed by ﬂow cytometry on at least 5 × 105 puriﬁed cells (purity≥ 95%). Isotypic control is shown as a thin line, BLT1 and 2
staining as bold lines. Pat: Patient; the letter in capital is the stage of thedisease at diagnosis, PI: proliferation index. B:Disease evolution and intracellular concentration of LTB4 (pg LTB4/μg
of proteins) as measured by ELISA assay.
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of B-CLL. Analyzed globally, normal B CD5 positive cells were readily
distinguished from B-CLL cells. Indeed, iPLA2-beta, 5LOX, LTA4H,
CYP4F3A, TXAS, PPAR-alpha, PPAR-gamma and LTB4 levels were raised
in B-CLL cells, in comparison with normal B CD5 positive cells. This sug-
gests that alterations of lipid metabolism may be important events in
the etiology of B-CLL. Lipid mediators are known to play important
roles in tissue homeostasis by providing energy sources that can fuel
in mitochondria metabolism [33]. In addition, they are involved in sig-
naling pathways, some of which may be deregulated in disease
[33–35]. They are also important in inﬂammation, especially the eicosa-
noids, such as leukotrienes and prostaglandins [34,35]. In this study, we
found that COX1, COX2, and TXAS enzymes were abundantly expressed
in B-CLL. However, in vitro blockade of TXAS with ozagrel™ resulted in
no signiﬁcant variation of the survival of control B CD5 positive cells and
tumor cells of patients with a favorable or an unfavorable clinical out-
come. This suggests that 12-HHT is not a major actor in the progression
of B-CLL disease.When no additionwasmade of inhibitors nor LTB4, theTable 3
Fold change in PPAR-alpha and PPAR-gamma expressions as measured by RT-qPCR using GAP
Stage A (n = 22) Stage B (n = 7)
PPAR-alpha 252.51 ± 47.47 194.61 ± 53.77
PPAR-gamma 6.91 ± 1.82 5.95 ± 3.51optical density observed for the tumor cells of patients with an adverse
evolution was superior to that found for the cells of patients without
adverse evolution. As equal number of cells were seeded per well and
as B-CLL tumor cells do not proliferate in vitro [1,3,4,13], it then seems
to us that this difference in optical densitiesmay be attributed to a lesser
death rate when the disease is aggressive rather than to a real prolifer-
ation.Moreover, as also observed by Secchiero et al. [11], only COX2was
over-expressed in tumor cells, in comparison with normal B CD5 posi-
tive lymphocytes. In addition, and in agreement with Ryan's study
[10], COX2 over-expression was signiﬁcantly more important when
the proliferative rate was high and thus the disease outcome was
poor. These two studies also demonstrated that COX2 over-expression
contributes to B-CLL tumor cells' survival and that selective COX2 inhib-
itors sensitize tumor cells to chlorambucil and TRAIL-induced apoptosis
in vitro for most of the patients. It was proposed that COX2 inhibitors
may act by modulating B-CLL tumor cells oxidative stress [36,37]. How-
ever, administration of the COX2 inhibitor celecoxib did not convincing-
ly improve the patients' condition, even though 3 of the 13 treated-DH expression as an internal standard and healthy B CD5 positive cells as a reference.
Stage C (n = 3) Slowly evolving Highly evolving
207.25 ± 47.96 242.86 ± 49.88 249.24 ± 50.27
16.91 ± 8.02 6.72 ± 2.28 18.08 ± 8.41
Fig. 8. The LTB4–BLT2, but not the LTB4–BLT1 or the 12-HHT, signaling pathway, is speciﬁcally required for the cell survival and proliferation of aggressive B-CLL cells. Cells were incubated
with orwithout 150nMLTB4and speciﬁc inhibitors. The vehiclewas ethanol, BLT1 inhibitor (U78502)was usedat theﬁnal concentration of 1.5 μM,BLT2 inhibitor (LY255283)wasusedat
10 μMand the TXAS inhibitor (ozagrel) at 20 μM. *=p b 0.05; **= p b 0.01. Surface expression of BLT1 and BLT2 as assessed byﬂow cytometrywas respectively 15±5% and 16±7% for
the controls, 20 ± 5% and 24 ± 7% for the cells of patients with a slowly progressing disease, and 31 ± 9% and 52 ± 10% for those of patients with an aggressive disease.
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cells count [38]. One reason for this poor efﬁcacy may be the involve-
ment of LTB4 in B-CLL tumor cells' survival. Indeed, these cells were
shown to produce LTB4, and speciﬁc LTB4 synthesis inhibitors
counteracted their CD40-dependent activation [12]. We also observed
the production of LTB4 by B-CLL tumor cells. However, plasma concen-
trations were not statistically different between patients and controls,
despite the fact that intracellular B-CLL concentrations of LTB4 were
higher than in normal B CD5 positive lymphocytes. In good agreement
with this observation, 5LOX and LTA4H mRNAs were more expressed
in B-CLL cells than in healthy CD5 positive cells, suggesting that the
5LOX and LTA4H enzymes, which produce LTB4, were more expressed
in tumor cells than in normal cells. Why then was there no increase in
circulating LTB4 in the patients' serum? One possibility stands from
the fact that CYP4F3A, which metabolizes LTB4 into 20-OH-LTB4, a
non-secreted compound, was also more abundant in B-CLL tumor cells
than in their normal counterparts. Consequently, the balance between
synthesis and inactivation may remain roughly constant, at least for
the patients whose tumor cells proliferate slowly, less than doubling
each year. In addition, 20-OH-LTB4 is known to repress BLT1 expres-
sion [15], possibly accounting for the fact that its expression remains
close to the one observed in normal B CD5 positive lymphocytes. The
situation seems different for patients with a rapidly progressing disease
when compared with those with a slowly progressing disease: they
show lower intracellular LTB4 concentrations despite lower CYP4F3A
and higher 5LOX and LTA4H expression. We therefore analyzed the ex-
pression of BLT1 and BLT2, the LTB4 receptors. While BLT1 expression
does not vary signiﬁcantly between the two groups of patients, the ex-
pression of BLT2 does, with a larger fraction of expressing cells when B-
CLL tumor cells are more proliferative. We then suggest, for those pa-
tients, that their tumor cells produce and secrete more LTB4, but that
the secreted LTB4 readily binds its membrane receptors BLT1 and
BLT2. Thismay thenprovide tumor cellswith new capacities, depending
on the mobilization of either BLT1 or BLT2, which have recently been
shown to have non-redundant physiological roles. BLT2 is indeed a
low afﬁnity receptor for LTB4 but also a receptor promoting cancer pro-
gression by activating the NF-κB transcription factor and the JAK/STAT3
pathway [39,40], which have also been associated with adverse evo-
lution in B-CLL [41,42]. To test this hypothesis, healthy B CD5 positive
and tumor cells of patients with a slowly or a highly proliferating dis-
ease were incubated with speciﬁc inhibitors for these receptors.
Blocking BLT1 did not have any effect on the different cellularpopulations, either in the presence of added LTB4 or not. However, de-
creased viability was observed for the cells from patients with an ag-
gressive disease when the speciﬁc BLT2 antagonist LY255283 was
added. This was especially true when LTB4 was added (p = 0.01) but
was also evidenced when no LTB4 was added (p = 0.05). As adding
LTB4 resulted in increased survival for both tumor cells of patients
with a favorable or an unfavorable clinical outcome, LTB4 trapping on
BLT2 thus appears as a mechanism especially involved in the aggres-
siveness of B-CLL. It then seems that mainly the lipoxygenases, but
also the cyclooxygenases, pathways contribute to B-CLL progression.
These pathways share a common metabolic precursor, arachidonic
acid (AA), whose amount may then be rate limiting for B-CLL prolifera-
tion. As intracellular AA is generated frommembrane phospholipids, es-
sentially by cPLA2-alpha and iPLA2-beta [6,9], we wondered whether
the expression of those enzymes might be altered in B-CLL tumor
cells. Normal B CD5 positive lymphocytes and B-CLL express both
cPLA2-alpha and iPLA2-beta but at varying levels. Consistent with
5LOX, COX1 and COX2 over-expression, PLA2 enzymes are more pres-
ent in tumor cells than in their normal counterparts. While iPLA2-beta
expression does not appear to be linked with the tumor stage, cPLA2-
alpha is more expressed in tumor cells when patients suffer from an ad-
vanced disease (stages B and C according to Binet classiﬁcation). How-
ever, of interest is the fact that over-expression of both PLA2s
correlates with a high proliferative index, as also observed for 5LOX,
LTA4H, COX1 and COX2. This may be relevant to the fact that both
iPLA2-beta and cPLA2-alpha have been proposed to promote cancer
progression by enhancing cell migration or cell proliferation [6,
43–46], on the condition that AA intracellular concentration remains
low, otherwise free AA is cytotoxic and promotes cell death [47]. Our
ﬁndings are consistent with these physiological roles for iPLA2-beta
and cPLA2-alpha.
LTB4 and its metabolite 20-OH-LTB4, prostaglandins and their
metabolites are bioactive lipids, which bind and activate the nuclear re-
ceptors and transcription factors PPAR-alpha and PPAR-gamma. In turn,
these regulate their synthesis and degradation, as demonstrated for
LTB4 and PPAR-alpha [9,19,21–23]. In our study, both receptors were
more expressed in circulating B-CLL tumor cells than in normal B CD5
positive lymphocytes. PPAR-gamma was signiﬁcantly more abundant
in tumor cells with a high proliferative index than in slowly growing
ones. This might seem surprising as PPAR-gamma is considered as a
tumor suppressor gene, although its main function relates to its role in
lipid metabolism [7,25,48]. Identifying PPAR-gamma target genes in
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Spaner et al. [49] recently demonstrated PPAR-alpha expression in cir-
culating B-CLL cells, as we did here. However, contrary to their results,
we found PPAR-alpha to be moderately expressed in normal B CD5
positive cells, but much more strongly in all B-CLL tumor cells, not
only in advanced stage disease. Discrepancy between the two studies
may relate to the techniques used. In Spaner's study, PPAR-alpha levels
were measured by Western-blotting for 26 B-CLL samples and RNA
quantitation for only 2 B-CLL samples. In the last cases, PPAR-alpha ex-
pression was moreover compared with that observed in the mononu-
clear cells from a single normal donor. Nevertheless, both studies,
together with that of Tung [50], are consistent with a putative role
for PPAR-alpha in the course of tumor progression. The ability of
PPAR-alpha and PPAR-gamma to allow fatty acids to be used as a source
of energy may surpass their potential tumor suppressor function.
5. Conclusion
Taken together our results demonstrate a deregulation of the path-
ways leading to LTB4 and prostaglandins synthesis. These alterations
affect the ﬁrst elements common to these pathways: cPLA2-alpha and
iPLA2-beta, together with 5LOX, LTA4H, COX1, COX2 and TXAS. This
starts from the early stage and is being ampliﬁed for tumor cells with
a high proliferative capacity, except for COX1 and TXAS. As a conse-
quence, prostaglandins and LTB4 can be synthesized, BLT1 and BLT2 ac-
tivated, thus allowing tumors to increase their survival and proliferative
potentials. In parallel, PPAR-alpha and PPAR-gamma seem to function
more as cancer promoting transcription factors rather than tumor sup-
pressor genes, enabling tumor cells to use fatty acids as an energy
source. The combined use of COX and LOX inhibitors may then be of
potential clinical interest in B-CLL treatment.
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